Nandrolone or Primobolan: What Is the Difference

Nandrolone and primobolan are often mentioned together as "mild" anabolics with moderate androgenicity. However, they come from different chemical families, are metabolized differently, and have different specific risks. The editorial team examines these differences on the basis of pharmacological data and clinical studies.

Two chemical families

Nandrolone is 19-nortestosterone, that is, the testosterone molecule without the methyl group at position 19. This seemingly minor change gives the substance several features: a different result of 5α-reductase action, a notable affinity for the progesterone receptor, and weaker aromatization.

Methenolone belongs to the derivatives of dihydrotestosterone (DHT). It has a 5α-reduced structure with a double bond at position 1 and a methyl group at the same position. Such molecules do not aromatize and are not substrates for 5α-reductase.

Both substances are used in the form of esters. Nandrolone is best known as the decanoate (Deca-Durabolin) and the phenylpropionate; methenolone as the enanthate for injections and the acetate for oral use.

Thus, what they share is mainly the reputation of "moderate" anabolics. At the molecular level, however, these are two different strategies: nandrolone loses part of its androgenicity through a special metabolism in tissues, methenolone through reduced overall activity.

Why nandrolone is "less androgenic" in the skin

In the skin, hair follicles, and prostate, testosterone under the action of 5α-reductase is converted into DHT, which binds to the androgen receptor more strongly. In this way the androgen signal in these tissues is enhanced.

With nandrolone the opposite happens. The same enzyme converts it into 5α-dihydronandrolone, which binds to the receptor more weakly than the parent molecule. As a result, in tissues with high 5α-reductase activity nandrolone's androgenic effect is weakened.

It is precisely this that explains the classic notion of nandrolone as a substance with a favorable ratio of anabolic to androgenic activity. This notion is based on animal models and, on the whole, is consistent with pharmacology, although quantitative estimates for humans are lacking.

Methenolone has a different mechanism: it does not interact with 5α-reductase at all. Its androgenicity in tissues is determined by its own affinity for the receptor, which is considered moderate.

Practical takeaway: both substances can cause acne, alopecia, and virilization, but through different mechanisms. Neither is free of androgenic effects.

Progestogenic activity and estrogens

A specific feature of nandrolone that methenolone lacks is the ability to bind to the progesterone receptor. Progestogenic activity enhances suppression of the pituitary's secretion of gonadotropins, that is, the negative feedback in the hormonal axis.

Because of this, nandrolone is considered one of the strongest suppressors of one's own testosterone among anabolics. Cases of prolonged hypogonadism after its discontinuation have been described. Methenolone also suppresses the axis, but without the progestogenic component.

As for estrogens: nandrolone aromatizes significantly more weakly than testosterone, yet a small amount of estradiol is formed. Methenolone does not aromatize at all.

In informal sources, nandrolone's progestogenic activity is linked to reduced libido and a risk of gynecomastia. The mechanisms of these effects probably combine an effect on the progesterone receptor and suppression of one's own testosterone, but controlled human studies are scarce.

Medical use: where the data are

Nandrolone decanoate has a much broader clinical history. It was used for anemia associated with chronic kidney disease, for osteoporosis in postmenopausal women in some countries, and also for wasting in the context of HIV infection.

One of the most cited studies is the randomized controlled trial by Johansen and colleagues (1999) in hemodialysis patients. Over six months nandrolone decanoate increased lean body mass and improved some functional indicators compared with placebo.

Methenolone was used for anemias due to bone marrow insufficiency and for wasting conditions, but there are practically no modern randomized studies with it. In most countries its pharmaceutical forms are no longer available.

It is worth emphasizing: even where nandrolone is still registered, it is prescribed for narrow indications and under a physician's supervision. The medical data give no grounds for conclusions about the safety of supraphysiological amounts in healthy people.

Risks and doping control

The shared risks of both substances include suppression of the hormonal axis, reduced HDL, an unfavorable effect on the myocardium and vessels, psycho-emotional changes, and virilization in women. These effects are described for the class of anabolic-androgenic steroids in general.

The differences specific to each substance look as follows:

• Nandrolone:pronounced and prolonged suppression of the hormonal axis, progestogenic effects, possible reduced libido, very long detectability of metabolites.
• Methenolone:absence of estrogenic effects with a risk of estrogen deficiency during suppression of one's own testosterone; with oral use — a greater effect on lipids via the liver.

As for doping control: both substances belong to section S1 of the WADA Prohibited List. Nandrolone's main metabolite, 19-norandrosterone, can form endogenously in small amounts, so a threshold concentration has been established for it, and to confirm exogenous origin laboratories use isotope analysis.

Metabolites of nandrolone decanoate are detectable for a long time after the last administration, which is due to the slow release of the long ester from the depot and accumulation in tissues. For methenolone, detection methods are also well established.

Editorial conclusions

Nandrolone is a 19-nor derivative with a special metabolism in tissues, progestogenic activity, and weak aromatization. Methenolone is a DHT derivative without aromatization and without interaction with 5α-reductase.

Nandrolone has a much broader medical evidence base, including randomized studies in dialysis patients. Methenolone is practically not used in modern medicine.

The shared risks of the class — suppression of the hormonal axis, dyslipidemia, effects on the heart — are inherent in both substances, while nandrolone stands out for its especially pronounced suppression.

We also recommend reading our materials on the progestogenic activity of nandrolone, on the classification of anabolic steroids by chemical structure, and on the recovery of the hormonal axis.

References

1. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
2. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 1999;281(14):1275–1281.
3. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001–1020.
4. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
5. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
6. World Anti-Doping Agency. The Prohibited List. International Standard. Montreal: WADA; 2025.